Product Information
CLORAZEPATE 3.75 MG TABLET is a generic product labeled by Aurolife Pharma LLC, priced at $0.5241 per EA under NDC 13107031905. Its NADAC has been published 237 times since Mar 23, 2022.
FDA first approved this application on Jul 17, 1987. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3.75 mg/1
Manufacturer
Aurolife Pharma LLCNDC
13107031905
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLORAZEPATE DIPOTASSIUMApproval Type
Generic (ANDA)
FDA Application
ANDA071858FDA Approved
7/17/1987
TE Code
AB
On Market Since
7/17/1987
Pharmacological Classes
Price Statistics
The NADAC for CLORAZEPATE 3.75 MG TABLET has been published 237 times since Mar 23, 2022, and over the history we have for it it has declined 43.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5241 per EA |
|---|---|
| All-time high | $1.3377 (Dec 14, 2022) |
| All-time low | $0.5241 (Sep 23, 2026) |
| 52-week high | $0.8878 |
| 52-week low | $0.5241 |
| Median price | $0.8237 |
| Average price | $0.8343 |
| Largest weekly change | +48.9% (Sep 18, 2024) |
| Weeks tracked | 237 |
| Tracking since | Mar 23, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurolife Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CLORAZEPATE DIPOTASSIUM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLORAZEPATE 3.75 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CLORAZEPATE 3.75 MG TABLET, manufactured by Aurolife Pharma LLC, is $0.5241 per EA (NDC 13107031905), effective Sep 30, 2026.
How has the price of CLORAZEPATE 3.75 MG TABLET changed over time?
Over the history we have for it, the NADAC for CLORAZEPATE 3.75 MG TABLET has declined 43.1%. It has been tracked across 237 weekly CMS publications since Mar 23, 2022.
What are the highest and lowest recorded NADAC prices for CLORAZEPATE 3.75 MG TABLET?
Since Mar 23, 2022, the NADAC for CLORAZEPATE 3.75 MG TABLET has ranged from a low of $0.5241 (Sep 23, 2026) to a high of $1.3377 (Dec 14, 2022), with a median of $0.8237 per EA.
Are there cheaper alternatives to CLORAZEPATE 3.75 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CLORAZEPATE 3.75 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CLORAZEPATE 3.75 MG TABLET?
CLORAZEPATE 3.75 MG TABLET (NDC 13107031905) is labeled by Aurolife Pharma LLC, and CMS classifies it as a generic product.